Allarity Therapeutics Inc (ALLR)
Allarity Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision medicine approaches for cancer treatment. The company works on developing anti-cancer therapeutics for patients with unmet medical needs and uses its proprietary drug response predictor technology to support personalized treatment and companion diagnostic development. Its lead candidate is stenoparib, a dual PARP1/2 inhibitor being studied in a phase 2 trial for patients with advanced and recurrent ovarian cancer. Allarity Therapeutics also develops stenoparib-DRP, a companion diagnostic intended to help identify select patients for stenoparib treatment. Incorporated in 2004, the company is headquartered in Boston, Massachusetts, and its common stock trades on NASDAQ under the symbol ALLR.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ALLR
|
$1
|
-16.6% Downside
|
Fair
|
$10.25
|
754.2% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
October 13, 2026
|
-1.7x
|
2.8x
|
55.3x
|
18.616 M
|
20.777 M
|
53.6%
|
98.1%
|
-5.9
|
—
|
148.4%
|
